2026
Clinical-Stage Nanatinostat Triggers Productive Epstein-Barr Virus Lytic Replication.
Journal of medical virology
PubMed • Publisher's siteResearch at a glance
Top areas of exploration
- Cell Line, Tumor , 12 publications
- Virus Activation , 11 publications
- B-Lymphocytes , 11 publications
- Virus Latency , 8 publications
Research activity
Focus
We study Epstein-Barr virus (EBV), the first human cancer-causing virus to be discovered. EBV causes infectious mononucleosis and is causal or linked to several B lymphocyte- and epithelial cell-cancers. Some of our experiments are designed to explore how EBV disturbs and exploits cellular physiology to drive unscheduled cell proliferation, a central feature of cancer. Other experiments are directed at understanding how this virus persists successfully in over 95% of humans. Both lines of investigation have revealed several targets for anti-cancer and anti-viral intervention.
My publications
Filter publications
58 publications
2026
Playing both sides - Epstein-Barr Virus accumulates select cellular transcripts to counter virus-mediated host shut-off in lytic cells.
PLoS pathogens
PubMed • Publisher's site2026
STING inhibits viral lytic reactivation and cell growth in primary effusion lymphoma.
Frontiers in immunology
PubMed • Publisher's site2025
Correction: STAT3, MYC, and EBNA1 cooperate through a ZC3H18 transcriptional network to regulate survival and proliferation of EBV-positive lymphomas.
PLoS pathogens
PubMed • Publisher's site2025
Leveraging the interconnected unfolded protein response and NLRP3 inflammasome pathways to reactivate Epstein–Barr virus in diffuse large B-cell lymphomas
NAR Cancer
Publisher's site